FDA Pauses Obesity Drug Study; Diabetic Eye Therapy OK’d; ‘Misleading’ Super Bowl Ad

The FDA ordered a clinical hold on a phase I study of the investigational obesity drug AMG 513, said developer Amgen.

Children’s Hospital Los Angeles has paused initiation of puberty blockers for transgender patients under age 19 after Trump’s executive order. (Los Angeles Times)

Also in line with a Trump executive order, Defense Secretary Pete Hegseth told the military to pause integrating new transgender recruits and suspend medical care for current service members with gender dysphoria. (The Hill)

Meanwhile, attorneys general of 15 states reaffirmed their commitment to protecting institutions that provide gender-affirming care in joint opposition to “any unlawful effort by the Trump Administration” to restrict access to therapies.

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory submission expected early next year.

The FDA approved ranibizumab (Susvimo) for diabetic macular edema, Genentech said.

Can testosterone help alleviate some symptoms of menopause? (New York Times)

Two senators sent a letter to the FDA about a “misleading” Super Bowl ad on weight-loss drugs offered by telehealth company Hims & Hers; the Partnership for Safe Medicines called the ad “dangerous.” (New York Times)

A study showed that nine patients with osteopetrosis had denser trabecular bone, thicker but looser cortical bone, unique bone patterns, and skeletal heterogeneity compared with healthy controls. (Journal of Clinical Endocrinology & Metabolism)

In an Italian cohort of type 1 diabetes patients who underwent intrahepatic or intraportal islet transplantation, median graft survival was 3.9 years, with a 40% graft survival rate at 20 years. (Lancet Diabetes & Endocrinology)

Please enable JavaScript to view the

comments powered by Disqus.